Kimia Biosciences Ltd (KIMI)

40.50 -1.10 (-2.64%)
Close INR Disclaimer

Kimia Biosciences Ltd Company Profile

Equity Type
Kimia Biosciences Ltd, formerly Laurel Organics Limited, is an India-based manufacturer of bulk drug intermediates. It manufactures bulk drugs intermediates for Indian pharmaceutical companies on contract manufacturing basis. The Company has approximately 30 intermediates of the therapeutic groups. It also offers finish goods and fine chemicals. The Company's commercial products include Benfotiamine, Cilnidipine, Gilclazide, Levosulpride, Rosuvastatin Calcium, Tranexamic Acid, Benidipine, Teneligliptin Hydrate Hydrobromide, Acotiamide, Luliconazole, Deflazacort, Voglibose, Oxaceprol, Ursodeoxycholic Acid, Tretinoin, Citicoline Sodium, and Isotretinoin.
Contact Information
Netaji Subhash Place Pitampura New Delhi,110034 India
91 11 4706 3600
91 11 4706 3601
Top Executives
Vipul Goel 0 2018 Non-Executive Non Independent Director
Jagdeep Dhawan 51 2016 Independent Non-Executive Director
Richa Gupta 41 2016 Independent Non-Executive Woman Director
Sameer Goel 47 2016 CEO, Chairman of the Board & MD
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles